Advancing transcatheter mitral valve repair
AVVie GmbH is developing a novel minimally invasive implant aimed at addressing a prolific heart valve condition affecting millions worldwide.
The Concept
Problem
More than 8 million people in Europe and the US suffer from moderate to severe mitral valve regurgitation. It is defined as backflow (leaking) of blood from the left ventricle into the left atrium of the heart due to insufficient valve closure. Symptoms include light-headedness, shortness of breath, fatigue and chest pain. While small leaks are usually not considered a problem, more severe cases weaken the heart over time and lead to heart failure.
State Of The Art
Open-heart surgery is the current gold-standard for treating mitral valve prolapse. Due to significant procedural risks for the patients, more than 50% of the affected patient population is currently left untreated.
Solution
The Mitral Butterfly implant is based on a unique physiological design which can be deployed in one-step via a minimally invasive transcatheter procedure.
Supported by
